<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144391</url>
  </required_header>
  <id_info>
    <org_study_id>03-02-511-07</org_study_id>
    <secondary_id>1U54HD041748-01</secondary_id>
    <nct_id>NCT00144391</nct_id>
  </id_info>
  <brief_title>Testosterone Gel Applied to Women With Pituitary Gland Problems</brief_title>
  <official_title>Physiologic Testosterone Replacement in Women With Hypopituitarism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles Drew University of Medicine and Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this study is to evaluate if application of testosterone gel leads to&#xD;
      improvement in measures of sexual function, thinking ability and quality of life in women&#xD;
      with dysfunction of the pituitary gland. A secondary purpose is to determine the effects of&#xD;
      testosterone replacement on body composition and muscle function and strength.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Testosterone is the principal male sex hormone but is also present in smaller amounts in&#xD;
      women and may be important for their health. Among its likely actions in women are the&#xD;
      building of bone and muscle mass, increase in interest in sex (libido) and effects on the&#xD;
      mood. Testosterone is commercially available as a hormone replacement therapy for males with&#xD;
      an absence or lack of testosterone production. Testosterone for males is mainly given in the&#xD;
      form of shots or skin patches which have certain disadvantages such as pain from shots and&#xD;
      skin rashes from patches. It is anticipated that this experimental gel application will&#xD;
      produce levels of the drug in the normal range in women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Testosterone and Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Testosterone and Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue Impact Scale</measure>
    <time_frame>6 months</time_frame>
    <description>change in fatigue impact scale there are 42 questions. Each question can be answered from 0 (no problem) to 4 (extreme problem), so a higher score indicates more severe fatigue impact. minimum score=0, maximum score =148 values are calculated at baseline and 6 months and the score at 6 months compared to baseline months is calculated</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Panhypopituitarism</condition>
  <arm_group>
    <arm_group_label>Transdermal Testosterone Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transdermal Testosterone Gel (2 mg per pump), 2 pumps per day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 pumps per day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal Testosterone gel</intervention_name>
    <description>2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Transdermal Testosterone Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women age 18-55&#xD;
&#xD;
          -  Hypopituitarism with central adrenal and/or gonadal deficiencies. To qualify patients&#xD;
             will need to have either 1 or 2 and they need to have 3:&#xD;
&#xD;
               1. To diagnose central adrenal deficiency, patients not on glucocorticoid&#xD;
                  replacement will have an insulin tolerance test (ITT) (patients with&#xD;
                  cardiovascular disease will be excluded) in which 0.1U/kg of insulin will be&#xD;
                  given by iv and a peak cortisol value of less than 20ug/dl, associated with a&#xD;
                  glucose level of less than 40mg/dL will be considered consistent with central&#xD;
                  adrenal insufficiency. Patients on glucocorticoid replacement will be evaluated&#xD;
                  by examining their prior workup and if it is determined that they had evidence of&#xD;
                  central adrenal deficiency, an ITT will not be required to document central&#xD;
                  adrenal deficiency (an ITT will still be performed to determine GH deficiency).&#xD;
&#xD;
               2. To diagnose central gonadal deficiency, patients will be asked if they had&#xD;
                  amenorrhea or oligomenorrhea prior to estrogen replacement. An FAH of less than 5&#xD;
                  MIU/ML will be used to confirm that they have central and not primary gonadal&#xD;
                  deficiency. In select patients in which the diagnosis of central gonadal&#xD;
                  deficiency is unclear, we may perform an LHRH stimulation test, in which 100 ug&#xD;
                  iv of LHRH (Factrel) will be given and a peak LH response of less than 15 MIU/ML&#xD;
                  will be considered consistent with central gonadotropin insufficiency.&#xD;
&#xD;
               3. Serum testosterone level on transdermal estrogen replacement of less than 20&#xD;
                  ng/dL or free testosterone of less than 1.5 pg/ml.&#xD;
&#xD;
          -  No other significant medical condition&#xD;
&#xD;
          -  Weight between 80 and 150% of ideal body weight&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  All races and ethnicities&#xD;
&#xD;
          -  All patients regardless of marital status and relationship status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Physical disabilities that would prevent them from participating in the study.&#xD;
&#xD;
          -  Current use of testosterone or other androgenic steroids. Patients who are taking&#xD;
             testosterone, DHEA or other androgen precursors will discontinue these&#xD;
             medications/supplements three months prior to the study.&#xD;
&#xD;
          -  Significant cardiopulmonary disease (prior myocardial infarction causing ventricular&#xD;
             dysfunction, angina, arrhythmias, congestive heart failure, valvular problem), venous&#xD;
             thrombotic event (pulmonary embolism or deep vein thrombosis), renal disease&#xD;
             (creatinine greater than 1.5 mg/dL), diabetes mellitus on insulin, uncontrolled&#xD;
             hypertension, malignancy (other than basal cell skin carcinoma) or major psychiatric&#xD;
             disease. Patients with depression or anxiety on a stable dose of medication will be&#xD;
             allowed to enroll.&#xD;
&#xD;
          -  Current abuse of illicit drugs or heavy ethanol use.&#xD;
&#xD;
          -  History of breast cancer or abnormal mammogram at entry. If patients with an abnormal&#xD;
             mammogram or PAP smear are appropriately evaluated and found not to have cancer, they&#xD;
             will be allowed to participate in the study.&#xD;
&#xD;
          -  Those with significant liver function abnormalities defined as SGOT, SGPT or alkaline&#xD;
             phosphatase value of greater than one and one-half the upper limit of normal in our&#xD;
             Clinical Pathology Laboratory or serum bilirubin levels of greater than 2 mg/dL will&#xD;
             be excluded.&#xD;
&#xD;
          -  Those with history of hyperandrogenic disorders such as hirsutism and polycystic ovary&#xD;
             disease will be excluded. These conditions are rare in women with hypopituitarism.&#xD;
             Testosterone administration to these patients may exacerbate the underlying disorder.&#xD;
&#xD;
          -  Women who are pregnant, seeking to become pregnant in the next 6 months, or&#xD;
             breast-feeding.&#xD;
&#xD;
          -  Those who have previously experienced intolerance to other transdermal systems or gels&#xD;
&#xD;
          -  Drugs known to alter testosterone production such as megace or ketoconazole.&#xD;
&#xD;
          -  Patients with untreated hyperprolactinemia or active Cushing's disease. Patients with&#xD;
             treated prolactinoma or Cushing's disease will be allowed to participate in the study.&#xD;
&#xD;
          -  Hematocrit of greater than 50%&#xD;
&#xD;
          -  Male sex&#xD;
&#xD;
          -  Not willing to answer all questions on surveys&#xD;
&#xD;
          -  EKG showing ischemia or prior myocardial infarction&#xD;
&#xD;
          -  Patients with extensive brain surgery, severe head injury, brain tumors or other&#xD;
             conditions that profoundly affect CNS function.&#xD;
&#xD;
          -  Patients not willing to be placed on a standardized hormonal replacement regimen&#xD;
             including transdermal estrogen and growth hormone.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore C Friedman, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles Drew University of Medicine and Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles Drew University of Medicine and Science</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.centerwatch.com</url>
    <description>Clinical Trial Research site</description>
  </link>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <results_first_submitted>April 14, 2017</results_first_submitted>
  <results_first_submitted_qc>May 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 27, 2017</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles Drew University of Medicine and Science</investigator_affiliation>
    <investigator_full_name>Theodore Friedman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transdermal Testosterone Gel</title>
          <description>Transdermal Testosterone gel- 2.0 mg per pump dose 2 pumps per thigh per day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo&#xD;
placebo gel- 2 pumps per thigh per day for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transdermal Testosterone Gel</title>
          <description>2.0 mg per pump dose. Study patients receive either 2 pumps per thigh per day of transdermal testosterone gel or 2 pumps of placebo per thigh per day for 6 months&#xD;
Transdermal Testosterone gel: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Transdermal Testosterone gel: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="9"/>
                    <measurement group_id="B2" value="42" spread="14"/>
                    <measurement group_id="B3" value="43" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fatigue Impact Scale</title>
        <description>change in fatigue impact scale there are 42 questions. Each question can be answered from 0 (no problem) to 4 (extreme problem), so a higher score indicates more severe fatigue impact. minimum score=0, maximum score =148 values are calculated at baseline and 6 months and the score at 6 months compared to baseline months is calculated</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transdermal Testosterone Gel</title>
            <description>2.0 mg per pump dose. Study patients receive either 2 pumps per thigh per day of transdermal testosterone gel or 2 pumps of placebo per thigh per day for 6 months&#xD;
Transdermal Testosterone gel: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Transdermal Testosterone gel: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Impact Scale</title>
          <description>change in fatigue impact scale there are 42 questions. Each question can be answered from 0 (no problem) to 4 (extreme problem), so a higher score indicates more severe fatigue impact. minimum score=0, maximum score =148 values are calculated at baseline and 6 months and the score at 6 months compared to baseline months is calculated</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.9" spread="29.5"/>
                    <measurement group_id="O2" value="2.2" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Transdermal Testosterone Gel</title>
          <description>2.0 mg per pump dose. Study patients receive either 2 pumps per thigh per day of transdermal testosterone gel or 2 pumps of placebo per thigh per day for 6 months&#xD;
Transdermal Testosterone gel: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Transdermal Testosterone gel: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hirsutism</sub_title>
                <description>patient developed increase in facial hair, oily hair and acne</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of patients recruited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Theodore Friedman</name_or_title>
      <organization>Charles R. Drew University of Medicine and Science</organization>
      <phone>310-668-5197</phone>
      <email>theodorefriedman@cdrewu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

